DA Davidson maintains Phreesia at Buy, raises price target to $15 from $13
DA Davidson reaffirmed its Buy rating for Phreesia and increased its price target to $15 from $13, citing a 22.3% upside from the Nov 18 close of $12.26.
Phreesia, Inc.
Phreesia provides an integrated software, payments and engagement platform for healthcare organizations, including ambulatory practices, health systems and hospitals, as well as life sciences companies, government entities and other organizations. Its tools support patients from finding and scheduling care through intake, payment and post-visit follow-up. The platform includes MediFind, an online provider directory, self-scheduling and referral management tools, digital intake and clinical data capture, patient engagement tools, payment and financing solutions, and measurement and analytics capabilities. Phreesia makes money through subscription and related services, payment solutions that include processing and financing fees, and Network Solutions, which enables life sciences companies and other organizations to deliver patient and provider engagement through annual, per-engagement contracts. The company is fully remote and does not maintain principal executive offices; its mailing address is in Wilmington, Delaware.
DA Davidson reaffirmed its Buy rating for Phreesia and increased its price target to $15 from $13, citing a 22.3% upside from the Nov 18 close of $12.26.
JP Morgan downgraded Phreesia to Underweight from Neutral, setting a price target of $13. This is near the stock's Nov 10 close of $13.13.
Citizens maintained a Market Perform rating on Phreesia (PHR) after mixed industry feedback. The stock trades at $11.28, with potential upside according to InvestingPro. Q2 2027 revenue rose 10% YoY to $129.5M, beating estimates, but EPS missed. Analysts have varied outlooks on growth and profitability.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PHR (Phreesia, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PHR coverage spans earnings, financial news and market movers.
In the last 30 days, PHR insiders filed 2 SEC Form 4 transactions — 2 purchases ($683) and no sales. The most active reporter was Linetsky David, President, Network Solutions, with 2 filings.
DA Davidson reaffirmed its Buy rating for Phreesia and increased its price target to $15 from $13, citing a 22.3% upside from the Nov 18 close of $12.26.
The downgrade signals reduced confidence, likely prompting sell pressure.
Mixed feedback and downgrade may weigh on the stock.
Improved margins and cash flow support upside, but slower growth and reduced visibility increase risk.
Strong profitability and debt reduction may support upside, but reduced visibility in network solutions and strained client base pose downside risks.
AlphAI scores every news story that mentions PHR with an AI model for sentiment and relevance, and aggregates insider trades from Phreesia, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DA Davidson reaffirmed its Buy rating for Phreesia and increased its price target to $15 from $13, citing a 22.3% upside from the Nov 18 close of $12.26.
JP Morgan downgraded Phreesia to Underweight from Neutral, setting a price target of $13. This is near the stock's Nov 10 close of $13.13.
Citizens maintained a Market Perform rating on Phreesia (PHR) after mixed industry feedback. The stock trades at $11.28, with potential upside according to InvestingPro. Q2 2027 revenue rose 10% YoY to $129.5M, beating estimates, but EPS missed. Analysts have varied outlooks on growth and profitability.
Phreesia (PHR) reported Q2 revenue of $129.5M (up 10%) and adjusted EBITDA of $32.9M (up 25%). Net income was $1.9M, marking 5 straight profitable quarters. Management reaffirmed FY guidance. Analysts are divided: some raised targets citing margin improvements, while others downgraded due to slower growth and healthcare IT pressures.
Phreesia (PHR) reported Q2 2027 revenue of $129.5M and adjusted EBITDA of $32.9M, marking five straight quarters of positive net income. Revenue grew 10% YoY, with client count and revenue per client also increasing. The company reduced debt by $23M and credited AI for operational efficiencies. However, management warned of increased unpredictability in network solutions revenue due to financial strain on healthcare providers. Phreesia reaffirmed its full-year revenue and EBITDA guidance.
Phreesia (PHR) reported Q2 2027 revenue of $129.5M, up 10% YoY, with adjusted EBITDA of $32.9M and net income of $1.9M. AHSCs grew 6% to 4,744. Full-year guidance: revenue $510M-$520M, adjusted EBITDA $125M-$135M. Management noted variability in revenue forecasting and economic pressures on healthcare providers.
Phreesia (PHR) stock fell 7% Tuesday due to bearish sentiment after Q2 earnings and a downgrade by Raymond James analyst John Ransom. Ransom cited declining organic revenue growth and AI spending pressures. Despite a 10% revenue increase, concerns remain about future performance and market constraints.
DA Davidson reduced its price target for Phreesia Inc. (NYSE:PHR) to $13.00 from $14.00, citing adjusted revenue assumptions and growth timelines. The firm maintained a Buy rating, noting mixed Q2 fiscal 2027 results with revenue of $129.5M and adjusted EBITDA of $32.9M. Phreesia's stock trades at $10.92, below analyst consensus targets ranging from $10 to $20.
Phreesia (PHR) shares fell 6.33% after reporting Q2 2027 revenue of $129.5M, up 10% YoY, and GAAP net income of $1.9M. While revenue beat estimates, earnings per share missed expectations. The company maintained full-year guidance and highlighted recent product launches.
Phreesia, Inc. (PHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phreesia Announces Second Quarter Fiscal 2027 Results ALL-REMOTE COMPANY/WILMINGTON, Del., September 2, 2026 – Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026. “Phreesia deli